Your browser is no longer supported. Please, upgrade your browser. Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Order: Signal: Tickers:
Overview Valuation Financial Ownership Performance Technical Custom Charts Tickers Quotes Basic TA News Snapshot
Total: 1 #1
CompanySarepta Therapeutics, Inc.
Market Cap694.42MEPS (ttm)-2.54
P/E-EPS this Y35.60%
Forward P/E-EPS next Y-8.90%
PEG-EPS past 5Y-9.80%
P/S56.00EPS next 5Y-0.20%
P/B2.41EPS Q/Q42.70%
Dividend-Sales Q/Q-73.80%
Insider Own0.20%Inst Own63.80%
Insider Trans38.58%Inst Trans-3.09%
Short Float35.70%EarningsNov 06/b
Analyst Recom2.60Target Price26.92
Avg Volume1.69M52W Range14.31 - 40.00
Nov-26-14Upgrade WBB Securities Buy → Strong Buy $25 → $25
Nov-26-14 09:25AMSarepta Therapeutics upgraded by WBB Securities
Nov-24-14 05:24PMIt was another slow, low volume, lackluster trading session Yahoo Finance Blogs
Nov-24-14 04:30PMSarepta Therapeutics to Host Webcast and Conference Call for the Duchenne Muscular Dystrophy Community on December 2, 2014 Business Wire
Nov-24-14 12:20PMBioMarin's Prosensa Buy: A 'Courageous' Acquisition? at
Nov-24-14 10:22AMBioMarin Buys Prosensa Backs Up Troubled Drug at Investor's Business Daily
Nov-24-14 09:19AMStock Futures Trending Higher; Kate Spade Bags An Upgrade at Investor's Business Daily
Nov-24-14 07:00AMSarepta Therapeutics to Present Company Overview at Upcoming Conferences Business Wire
Nov-18-14 03:24PMRobbins Arroyo LLP Is Investigating the Officers and Directors of Sarepta Therapeutics, Inc. (SRPT) on Behalf of Shareholders PR Newswire
Nov-18-14 09:15AMSarepta Therapeutics Announces First Patient Dosed in Confirmatory Study of Eteplirsen in Ambulant Patients with Duchenne Muscular Dystrophy Business Wire
Nov-14-14 06:16PMINVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Sarepta Therapeutics, Inc. (SRPT) To Contact The Firm PR Newswire
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. Its lead product candidate is Eteplirsen, an antisense PMO-based therapeutic in clinical development for the treatment of individuals with Duchenne muscular dystrophy. The company is also involved in developing treatments that are in clinical development include AVI-7288 for the treatment of Marburg virus and AVI-7100 for the treatment of influenza. In addition, it focuses on developing preclinical research product candidates for the treatment of other neuromuscular, infectious, and rare diseases. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.